Published in Gastroenterology on May 21, 2012
ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol (2015) 3.22
Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. Gastroenterology (2013) 1.92
Surveillance for low-grade dysplastic Barrett's oesophagus: one size fits all? World J Surg (2015) 1.45
Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett's esophagus. Dig Dis Sci (2014) 1.44
Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2014) 1.40
BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol (2015) 1.17
Post-ablation surveillance in Barrett's esophagus: A review of the literature. World J Gastroenterol (2016) 0.85
Correlation of the presence and extent of loss of heterozygosity mutations with histological classifications of Barrett's esophagus. BMC Gastroenterol (2012) 0.81
Assessment of mutational load in biopsy tissue provides additional information about genomic instability to histological classifications of Barrett's esophagus. J Gastrointest Cancer (2014) 0.79
Role of interleukin-6 in Barrett's esophagus pathogenesis. World J Gastroenterol (2013) 0.78
Barrett's esophagus: who should receive ablation and how can we get the best results? Gastroenterology (2012) 0.76
Endoscopic assessment and management of early esophageal adenocarcinoma. World J Gastrointest Oncol (2014) 0.76
The essence of management of Barrett's esophagus. Gastrointest Endosc (2013) 0.75
Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus. Dig Dis Sci (2014) 0.75
Outcomes of Radiofrequency Ablation for Dysplastic Barrett's Esophagus: A Comprehensive Review. Gastroenterol Res Pract (2016) 0.75
Barrett's Esophagus: Diagnosis and Management. Gastrointest Endosc (2017) 0.75
Managing Barrett's esophagus with radiofrequency ablation. Gastroenterol Rep (Oxf) (2013) 0.75
Low grade dysplasia in Barrett's esophagus: Should we worry? World J Gastrointest Pathophysiol (2014) 0.75
Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett's esophagus may not be benign. Endosc Int Open (2016) 0.75
Update on the use of radiofrequency ablation for treatment of barrett esophagus. Gastroenterol Hepatol (N Y) (2013) 0.75
Reflux and Barrett's disease: revival of endoscopic antireflux procedures? Endoscopy (2013) 0.75
Ablative therapy for esophageal dysplasia and early malignancy: focus on RFA. Biomed Res Int (2014) 0.75
Ablation Therapy for Barrett's Esophagus: New Rules for Changing Times. Curr Gastroenterol Rep (2017) 0.75
Predictors of Progression in Barrett's Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry. Am J Gastroenterol (2017) 0.75
Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA (1996) 14.23
Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med (2009) 10.91
Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med (2002) 8.72
Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med (2011) 8.62
Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA (1996) 8.52
The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA (1996) 6.80
Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology (2001) 5.80
Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology (2000) 4.74
Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc (2007) 3.53
Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology (2011) 3.44
Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med (2003) 3.30
Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology (2002) 3.28
Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc (2008) 3.13
Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy (2010) 3.12
Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2006) 3.06
Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol (2000) 2.99
Endoscopic complications. Results of the 1974 American Society for Gastrointestinal Endoscopy Survey. JAMA (1976) 2.55
Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst (2004) 2.53
The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut (2011) 2.51
Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc (2008) 2.51
American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50
Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol (1999) 2.50
Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut (1998) 2.38
Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut (1991) 2.29
Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol (2009) 2.28
Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology (2011) 2.27
The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol (1999) 2.26
Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg (1994) 2.25
Properties of the neosquamous epithelium after radiofrequency ablation of Barrett's esophagus containing neoplasia. Am J Gastroenterol (2009) 2.05
Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg (1993) 2.00
A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology (2009) 1.95
Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology. Gastroenterology (1997) 1.92
Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol (2010) 1.90
Radiofrequency ablation of Barrett's esophagus: outcomes of 429 patients from a multicenter community practice registry. Endoscopy (2010) 1.83
Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol (1997) 1.81
Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making (2002) 1.78
Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy (2008) 1.71
Circumferential and focal ablation of Barrett's esophagus containing dysplasia. Am J Gastroenterol (2009) 1.69
Patient-derived health state utilities for gastroesophageal reflux disease. Am J Gastroenterol (2005) 1.64
The quality of care in Barrett's esophagus: endoscopist and pathologist practices. Am J Gastroenterol (2001) 1.63
A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol (1994) 1.59
Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy? Ann Thorac Surg (1992) 1.54
Panel on cost-effectiveness in health and medicine. Med Care (1996) 1.50
Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review. Am J Gastroenterol (2011) 1.50
Stepwise circumferential and focal ablation of Barrett's esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. Endoscopy (2008) 1.48
Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Am J Gastroenterol (2011) 1.36
A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system). Endoscopy (2008) 1.29
Treatment of ultralong-segment Barrett's using focal and balloon-based radiofrequency ablation. Surg Endosc (2009) 1.20
Early experience with radiofrequency energy ablation therapy for Barrett's esophagus with and without dysplasia. Dis Esophagus (2007) 1.13
Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. Am J Gastroenterol (1997) 1.12
Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective? Am J Gastroenterol (2000) 1.11
The role of radiofrequency ablation in the management of Barrett's esophagus. Gastrointest Endosc Clin N Am (2011) 1.11
Esophageal and pharyngeal strictures: report on 1,862 endoscopic dilatations using the Savary-Gilliard technique. Eur Arch Otorhinolaryngol (2007) 1.10
Low-grade dysplasia in Barrett's esophagus has a high risk of progression. Endoscopy (2007) 1.09
Pilot series of radiofrequency ablation of Barrett's esophagus with or without neoplasia. Endoscopy (2008) 1.05
Minimally invasive esophagectomy for Barrett's esophagus with high-grade dysplasia. Surgery (2000) 1.05
Endoscopic endoluminal radiofrequency ablation of Barrett's esophagus: initial results and lessons learned. Surg Endosc (2009) 0.99
How to manage a Barrett's esophagus patient with low-grade dysplasia. Clin Gastroenterol Hepatol (2008) 0.97
Transhiatal vs extended transthoracic resection in oesophageal carcinoma: patients' utilities and treatment preferences. Br J Cancer (2002) 0.91
Quality of life in patients with Barrett's esophagus undergoing surveillance. Am J Gastroenterol (2002) 0.90
Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma. PLoS One (2010) 0.87
When to consider endoscopic ablation therapy for Barrett's esophagus. Curr Opin Gastroenterol (2010) 0.85
Radiofrequency ablation of Barrett's esophagus: short-term results. Ann Thorac Surg (2009) 0.84
Unsedated small-caliber esophagogastroduodenoscopy (EGD): less expensive and less time-consuming than conventional EGD. J Clin Gastroenterol (2001) 0.80
American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol (2009) 12.16
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02
American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology (2011) 5.93
Comprehensive volumetric optical microscopy in vivo. Nat Med (2006) 5.19
Optical coherence tomography to identify intramucosal carcinoma and high-grade dysplasia in Barrett's esophagus. Clin Gastroenterol Hepatol (2006) 3.28
Radiation doses to ERCP patients are significantly lower with experienced endoscopists. Gastrointest Endosc (2010) 3.10
Comprehensive microscopy of the esophagus in human patients with optical frequency domain imaging. Gastrointest Endosc (2008) 2.94
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 2.77
Treatment of Barrett's esophagus with high-grade dysplasia or cancer: predictors of surgical versus endoscopic therapy. Clin Gastroenterol Hepatol (2008) 2.74
Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst (2004) 2.53
American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50
A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol (2008) 2.39
Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol (2006) 2.38
Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol (2010) 2.37
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
AGA Institute review of endoscopic sedation. Gastroenterology (2007) 2.35
Tethered capsule endomicroscopy enables less invasive imaging of gastrointestinal tract microstructure. Nat Med (2013) 2.32
Identifying intestinal metaplasia at the squamocolumnar junction by using optical coherence tomography. Gastrointest Endosc (2006) 2.31
Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst (2012) 2.30
The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol (2010) 2.30
Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc (2010) 2.28
Comprehensive esophageal microscopy by using optical frequency-domain imaging (with video). Gastrointest Endosc (2007) 2.26
Prediction of Barrett's esophagus among men. Am J Gastroenterol (2013) 2.22
National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med (2009) 2.19
Do breaks in gastroenterology fellow endoscopy training result in a decrement in competency in colonoscopy? Gastrointest Endosc (2013) 2.18
Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointest Endosc (2008) 2.09
Exploring utilities and outcomes with infliximab therapy. Clin Gastroenterol Hepatol (2006) 2.04
Trends in esophageal adenocarcinoma incidence and mortality. Cancer (2012) 2.03
Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc (2008) 1.96
Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. Gastrointest Endosc (2010) 1.79
Image-guided biopsy in the esophagus through comprehensive optical frequency domain imaging and laser marking: a study in living swine. Gastrointest Endosc (2009) 1.79
Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol (2009) 1.74
Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver Transpl (2011) 1.67
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol (2008) 1.57
A cost-utility analysis of secondary prophylaxis for variceal hemorrhage. Am J Gastroenterol (2004) 1.51
Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics (2009) 1.48
National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology (2009) 1.48
Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett's esophagus. Dig Dis Sci (2014) 1.44
Improving colorectal cancer screening and care in the Veterans Affairs Healthcare system. Clin Colorectal Cancer (2009) 1.41
Systematic review of the predictors of recurrent hemorrhage after endoscopic hemostatic therapy for bleeding peptic ulcers. Am J Gastroenterol (2008) 1.38
Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care (2010) 1.35
Cancer incidence among patients of the U.S. Veterans Affairs Health Care System. Mil Med (2012) 1.33
American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology (2013) 1.32
A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res (2008) 1.27
Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer (2008) 1.26
The impact of rotating shift work on the prevalence of irritable bowel syndrome in nurses. Am J Gastroenterol (2010) 1.26
Convergent evolution of novel protein function in shrew and lizard venom. Curr Biol (2009) 1.25
Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol (2007) 1.25
XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk. Carcinogenesis (2007) 1.25
Temporally and spectrally resolved fluorescence spectroscopy for the detection of high grade dysplasia in Barrett's esophagus. Lasers Surg Med (2003) 1.21
Endoscopic mucosal resection: an improved diagnostic procedure for early gastroesophageal epithelial neoplasms. Am J Surg Pathol (2006) 1.20
Women patients' preference for women physicians is a barrier to colon cancer screening. Gastrointest Endosc (2005) 1.20
Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointest Endosc (2011) 1.18
The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology (2011) 1.18
Factors associated with esophageal stricture formation after endoscopic mucosal resection for neoplastic Barrett's esophagus. Gastrointest Endosc (2011) 1.16
Helicobacter pylori in patients can be killed by visible light. Lasers Surg Med (2005) 1.15
Comprehensive imaging of gastroesophageal biopsy samples by spectrally encoded confocal microscopy. Gastrointest Endosc (2009) 1.15
Optical coherence tomography of the biliary tree during ERCP. Gastrointest Endosc (2002) 1.14
Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol (2006) 1.14
Meta-analysis of the association between HLA-DRB1 allele and rheumatoid arthritis susceptibility in Asian populations. J Korean Med Sci (2007) 1.10
Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus. Am J Gastroenterol (2010) 1.10
Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol (2012) 1.09
Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett's esophagus. Gastroenterology (2013) 1.09
Multiple-fiber probe design for fluorescence spectroscopy in tissue. Appl Opt (2002) 1.09
Buried dysplasia and early adenocarcinoma arising in barrett esophagus after porfimer-photodynamic therapy. Am J Surg Pathol (2007) 1.09
Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer (2014) 1.08
Cost-effective treatment of patients with symptomatic cholelithiasis and possible common bile duct stones. J Am Coll Surg (2011) 1.07
Patient predictors of esophageal stricture development after photodynamic therapy. Clin Gastroenterol Hepatol (2008) 1.07
Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. Dig Dis Sci (2003) 1.07
Optoacoustic tomography using time-resolved interferometric detection of surface displacement. J Biomed Opt (2003) 1.05
Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal (2012) 1.05
Management of superficial Barrett's epithelium-related neoplasms by endoscopic mucosal resection: clinicopathologic analysis of 27 cases. Am J Surg Pathol (2005) 1.02
Pragmatic classification of superficial neoplastic colorectal lesions. Gastrointest Endosc (2009) 1.02
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis (2008) 1.01
Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol (2005) 1.01
Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS (2015) 0.99
Why you should care about screening flexible sigmoidoscopy. N Engl J Med (2012) 0.99
Reflectance confocal microscopy for the diagnosis of eosinophilic esophagitis: a pilot study conducted on biopsy specimens. Gastrointest Endosc (2011) 0.98
Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett's oesophagus. Gut (2013) 0.98
Hospitalizations are increasing among minority patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis (2010) 0.96
Development of an empirically calibrated model of gastric cancer in two high-risk countries. Cancer Epidemiol Biomarkers Prev (2008) 0.95
Management of obscure occult gastrointestinal bleeding: a cost-minimization analysis. Clin Gastroenterol Hepatol (2008) 0.95
On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol (2007) 0.94
Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists. Dig Dis Sci (2010) 0.94
Projected costs, risks, and benefits of expanded newborn screening for MCADD. Pediatrics (2010) 0.93
Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems. BMC Cancer (2008) 0.93
Quality-of-life assessment of fibroid treatment options and outcomes. Radiology (2011) 0.93
Quality of life and mental health in family caregivers of patients with terminal cancer. Support Care Cancer (2011) 0.92
Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol (2010) 0.92
Detection of high-grade dysplasia in Barrett's esophagus by spectroscopy measurement of 5-aminolevulinic acid-induced protoporphyrin IX fluorescence. Gastrointest Endosc (2002) 0.92
Quality indicators for EGD. Gastrointest Endosc (2014) 0.92
Race and inflammatory bowel disease in an urban healthcare system. Dig Dis Sci (2010) 0.90
Patient predictors of histopathologic response after photodynamic therapy of Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma. Gastrointest Endosc (2008) 0.89
In search of quality colonoscopy. Gastroenterology (2008) 0.89
Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model. Radiology (2014) 0.88